EP
VYNT

Eudaimonia Partners’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Eudaimonia Partners’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6
Closed – – 1466
2021
Q1 		$0 Buy
+6
New +$152 ﹤0.01% 1673

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BF
Blankinship & Foster Solana Beach, California $452M AUM 16.63% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eudaimonia Partners's VYNT Position: Q2 2021 in Review

Eudaimonia Partners sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2021, closing a stake of 6 shares.

Eudaimonia Partners first reported a position in VYNT in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 29 funds tracked by Wall St. Rank hold VYNT as of Q2 2021.

  • Eudaimonia Partners reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 6 Vyant Bio, Inc. Common Stock shares in Q2 2021.
  • Eudaimonia Partners first reported a position in Vyant Bio, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's Vyant Bio, Inc. Common Stock position peaked at $0 in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.